NCT01147965View on ClinicalTrials.gov

Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Colon CancerLung CancerBreast Cancer
Interventions
BIOLOGICAL

AD5 CEA Vaccine

AD5\[E1-, E2b-\]-CEA Vector Vaccine

Trial Locations (2)

27710

Duke Cancer Research Institute, Duke University, Durham

99208

Medical Oncology Associates, PS, Spokane

Sponsors

Collaborators (1)

Duke University
All Listed Sponsors
collaborator

Duke University

OTHER

lead

Etubics Corporation

INDUSTRY